论文部分内容阅读
目的观察GNP(吉西他滨、奈达铂联合甲泼尼松龙)联合化疗治疗难治复发非霍奇金淋巴瘤的疗效。方法对本科2009年1月-2013年7月自愿接受GNP化疗的30例难治复发非霍奇金淋巴瘤住院患者进行疗效及不良反应的回顾性分析。其中难治12例,复发13例,进展5例。类型包括B细胞淋巴瘤18例,T细胞或NK/T细胞淋巴瘤12例。接受治疗的中位周期数为2(2~7)个疗程。结果 2个周期GNP治疗,显示完全缓解(complete remission,CR)3例,部分缓解(partial remission,PR)20例,稳定(stable disease,SD)7例。总反应率(over response rate,ORR)为76.7%,1年总生存率(over survival,OS)为86.7%,无进展生存(progression-free survival,PFS)占40%,中位PFS为10个月(95%CI:5.8~14.2个月)。不良反应轻,耐受性良好。结论 GNP联合化疗治疗难治复发非霍奇金淋巴瘤可以取得良好的疗效。
Objective To observe the curative effect of GNP (gemcitabine, nedaplatin combined with methylprednisolone) and chemotherapy in the treatment of refractory recurrent non-Hodgkin’s lymphoma. Methods A retrospective analysis of the efficacy and adverse reactions of 30 refractory recurrent non-Hodgkin’s lymphoma patients admitted to our hospital from January 2009 to July 2013 was conducted. Including refractory in 12 cases, 13 cases of recurrence, progress in 5 cases. Types include 18 cases of B-cell lymphoma, T-cell or NK / T-cell lymphoma in 12 cases. The median number of cycles treated was 2 (2 to 7) sessions. Results Two cycles of GNP showed complete remission (CR) in 3 cases, partial remission (PR) in 20 cases and stable disease (SD) in 7 cases. The overall response rate (ORR) was 76.7%. The 1-year over-survival (OS) was 86.7%, the progression-free survival (PFS) was 40%, and the median PFS was 10 Month (95% CI: 5.8-14.2 months). Adverse reactions are mild and well tolerated. Conclusion GNP combined with chemotherapy for the treatment of refractory recurrent non-Hodgkin’s lymphoma can achieve good results.